Drug Profile

Acute myeloid leukemia chimeric antigen receptor T-cell therapy - T-CURX

Latest Information Update: 29 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Wuerzburg
Developer T-CURX
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

18 Nov 2022 Acute myeloid leukemia chimeric antigen receptor T-cell therapy - T-CURX is available for licensing as of 18 Nov 2022. https://t-curx.com/company
10 Oct 2022 Preclinical trials in Acute myeloid leukaemia in Germany (Parenteral) (T-CURX pipeline, October 2022)
18 Mar 2021 T-CURX plans a clinical trial for Acute myeloid leukemia

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com